

# Bakhtiar Yamini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4713064/publications.pdf>

Version: 2024-02-01

32  
papers

1,218  
citations

471509

17  
h-index

414414

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

2437  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
2	DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF- $\kappa$ B p50 and a single nucleotide in the I $\kappa$ B-site. <i>Nucleic Acids Research</i> , 2013, 41, 764-774.	14.5	153
3	Nuclear factor- $\kappa$ B in glioblastoma: insights into regulators and targeted therapy. <i>Neuro-Oncology</i> , 2016, 18, 329-339.	1.2	103
4	Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 149-157.	3.3	83
5	Loss of Nfkb1 leads to early onset aging. <i>Aging</i> , 2014, 6, 931-942.	3.1	78
6	Temozolomide Treatment Induces lncRNA MALAT1 in an NF- $\kappa$ B and p53 Codependent Manner in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2536-2548.	0.9	71
7	Initial endoscopic management of pineal region tumors and associated hydrocephalus: clinical series and literature review. <i>Journal of Neurosurgery: Pediatrics</i> , 2004, 100, 437-441.	1.3	68
8	<i>BCL3</i> expression promotes resistance to alkylating chemotherapy in gliomas. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	52
9	p50 (NF- $\kappa$ B1) Is an Effector Protein in the Cytotoxic Response to DNA Methylation Damage. <i>Molecular Cell</i> , 2011, 44, 785-796.	9.7	49
10	MIB-1 Proliferation Index Predicts Survival among Patients with Grade II Astrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 931-936.	1.7	47
11	Transcriptional Targeting of Adenovirally Delivered Tumor Necrosis Factor $\kappa$ B by Temozolomide in Experimental Glioblastoma. <i>Cancer Research</i> , 2004, 64, 6381-6384.	0.9	45
12	NF- $\kappa$ B, Mesenchymal Differentiation and Glioblastoma. <i>Cells</i> , 2018, 7, 125.	4.1	44
13	Inhibition of Nuclear Factor- $\kappa$ B Activity by Temozolomide Involves <i>O</i> <sup>6</sup> -Methylguanine-Induced Inhibition of p53 DNA Binding. <i>Cancer Research</i> , 2007, 67, 6889-6898.	0.9	36
14	Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors. <i>World Neurosurgery</i> , 2018, 117, e698-e704.	1.3	33
15	Adenovirally Delivered Tumor Necrosis Factor- $\kappa$ B Improves the Antiglioma Efficacy of Concomitant Radiation and Temozolomide Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 6217-6223.	7.0	31
16	An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma. <i>Cancers</i> , 2021, 13, 1953.	3.7	26
17	Convection-enhanced delivery for treatment of brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, S79-S85.	2.4	23
18	DDX39B interacts with the pattern recognition receptor pathway to inhibit NF- $\kappa$ B and sensitize to alkylating chemotherapy. <i>BMC Biology</i> , 2020, 18, 32.	3.8	16

#	ARTICLE	IF	CITATIONS
19	Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. <i>Cancer Research</i> , 2015, 75, 2039-2048.	0.9	15
20	S-phase-dependent p50/NF- $\kappa$ B1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability. <i>Cell Cycle</i> , 2015, 14, 566-576.	2.6	14
21	CDK1 is up-regulated by temozolomide in an NF- $\kappa$ B dependent manner in glioblastoma. <i>Scientific Reports</i> , 2021, 11, 5665.	3.3	14
22	Endoscopic Approach to Noncommunicating Fluid Spaces in the Shunted Patient. <i>Pediatric Neurosurgery</i> , 1999, 31, 237-241.	0.7	8
23	Primary Sellar Paraganglioma: Case Report with Literature Review and Immunohistochemistry Resource. <i>World Neurosurgery</i> , 2019, 125, 32-36.	1.3	8
24	p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability. <i>Nature Communications</i> , 2020, 11, 5007.	12.8	8
25	Cerebrospinal fluid hydrocephalus shunting: cisterna magna, ventricular frontal, ventricular occipital. <i>Neurosurgical Review</i> , 2022, 45, 2615-2638.	2.4	6
26	Chemoinducible gene therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 1053-1058.	1.4	5
27	p52 signaling promotes cellular senescence. <i>Cell and Bioscience</i> , 2022, 12, 43.	4.8	4
28	Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105996.	1.6	3
29	Nfkb1 suppresses DNA alkylation-induced tumor formation. <i>Molecular and Cellular Oncology</i> , 2015, 2, e968073.	0.7	2
30	Surgery for low-grade gliomas: current evidence and controversies. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 13-19.	2.8	1
31	Intracranial hemorrhage as initial manifestation of plasma cell myeloma: A case report. <i>Journal of Clinical Neuroscience</i> , 2018, 50, 133-135.	1.5	1
32	Nfkb1/p50 and mammalian aging. <i>Oncotarget</i> , 2015, 6, 3471-3472.	1.8	1